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Clostridium perfringens epsilon toxin vaccine candidate lacking
toxicity to cells expressing myelin and lymphocyte protein
Helen Morcrette1, Monika Bokori-Brown 1, Stephanie Ong1, Leo Bennett1, Brendan W. Wren 2, Nick Lewis3 and Richard W. Titball 1
A variant form of Clostridium perfringens epsilon toxin (Y30A-Y196A) with mutations, which shows reduced binding to Madin–Darby
canine kidney (MDCK) cells and reduced toxicity in mice, has been proposed as the next-generation enterotoxaemia vaccine. Here
we show that, unexpectedly, the Y30A-Y196A variant does not show a reduction in toxicity towards Chinese hamster ovary (CHO)
cells engineered to express the putative receptor for the toxin (myelin and lymphocyte protein; MAL). The further addition of
mutations to residues in a second putative receptor binding site of the Y30A-Y196A variant further reduces toxicity, and we
selected Y30A-Y196A-A168F for further study. Compared to Y30A-Y196A, Y30A-Y196A-A168F showed more than a 3-fold reduction
in toxicity towards MDCK cells, more than a 4-fold reduction in toxicity towards mice and at least 200-fold reduction in toxicity
towards CHO cells expressing sheep MAL. The immunisation of rabbits or sheep with Y30A-Y196A-A168F induced high levels of
neutralising antibodies against epsilon toxin, which persisted for at least 1 year. Y30A-Y196A-A168F is a candidate for development
as a next-generation enterotoxaemia vaccine.
npj Vaccines            (2019) 4:32 ; https://doi.org/10.1038/s41541-019-0128-2
INTRODUCTION
Epsilon toxin is one of the major toxins produced by Clostridium
perfringens.1 The toxin is produced by the bacterium as a
prototoxin, which is activated by proteolysis, with the consequent
release of carboxy-terminal and amino-terminal peptides from the
protein.2–4 This toxin is important in the field of veterinary
medicine because it plays a major role in the development of
enterotoxaemia of sheep and goats, and occasionally of other
livestock animals. The toxin is produced in the gut of these
animals, often following the sudden ingestion of feedstuffs rich in
carbohydrates.5,6 By an unknown mechanism(s), the toxin crosses
the gut wall and enters the blood stream, becoming preferentially
targeted to the kidney, heart, lungs, and brain, and causing
oedema. The disease is often called pulpy kidney, although lesions
in the kidneys of affected animals are not observed. Effects on the
central nervous system result in neurological symptoms,7 and in
many animals the disease is rapidly fatal. Consequently, the
disease is of global economic significance. More recently, evidence
has been presented that epsilon toxin may play a role in the
development of multiple sclerosis in humans.8,9
The toxin acts by binding to host cells, and there is evidence
that seven monomers of the protein assemble into a pore, which
spans the cell membrane,10 resulting in unregulated ion move-
ment across the membrane and cell death.11 The identity of the
cell surface receptor for the toxin is still not fully clarified.
However, there is good evidence that the toxin binds to myelin
and lymphocyte protein (MAL).12,13 CHO cells, which are normally
highly resistant to the toxin, become sensitive when expressing
MAL,12,13 and MAL knockout mice are reported to be highly
resistant to the toxin.12 Other proteins that have been shown to
play a role in epsilon toxin binding may play accessory roles in
toxin binding.14–16
A number of commercial vaccines are available for the
prevention of enterotoxaemia. They are typically produced by
treating a C. perfringens culture filtrate with formaldehyde,
resulting in detoxification of epsilon toxin. These vaccines contain
proteins in addition to epsilon toxin, and there can be
considerable batch-to-batch variation in the immunogenicity of
these preparations. Inflammatory responses following vaccination
have been reported to result in reduced feed consumption. These
shortfalls have prompted work to devise improved vaccines, and a
number of recombinant immunogens have been reported,
including formaldehyde-treated epsilon toxin produced from
Escherichia coli17 and site-directed mutants (genetic toxoids) of
epsilon toxin with reduced toxicity.11,18–22 Site-directed mutants
offer the advantage that chemical detoxification, a process that
can result in batch-to-batch variation in immunogenicity, is
avoided. However, the high potency of the toxin can make it
difficult to completely abolish toxicity. The toxicity of the mutants
has, until now, been assessed using either Madin–Darby canine
kidney (MDCK) cell cultures or in mice.
We have previously constructed and tested a site-directed
mutant of epsilon toxin (Y30A-Y196A).20 This mutant had >430-
fold decrease in cytotoxicity towards MDCK cells compared with
the wild-type toxin and showed reduced toxicity in mice. In this
study, we report that unexpectedly this mutant showed only
marginal changes in toxicity towards CHO cells expressing sheep
or human MAL (hMAL). We have therefore set out to identify
mutations that could be incorporated into the Y30A-Y196A
mutant to reduce toxicity towards CHO cells expressing MAL.
We have tested these mutants in MDCK.2 cells and in CHO cells
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expressing MAL in mice and in sheep. These mutants are
promising genetic toxoids for incorporation into next-generation
enterotoxaemia vaccines.
RESULTS
Mutagenesis of residues flanking the β-octyl-glucoside binding
site
In a previous study, we identified a glycan (β-octyl-glucoside)
binding site in domain 3 of epsilon toxin, and suggested that this
site may be a second receptor binding site.19 Here we selected five
residues within or flanking this site for mutagenesis (V72, F92,
H149, V166, A168; Fig. 1a) to evaluate their role in toxicity. Using a
plasmid template, which encoded the Y30A-Y196A variant form of
epsilon prototoxin,20 residues V72, F92, H149, V166 or A168 were
mutated to alanine (F92, H149, V166) or phenylalanine (V72, A168)
and the His-tagged proteins encoded by the mutated genes were
expressed in E. coli and purified (Fig. 1b). We also expressed and
purified the Y30A-Y196A variant form of epsilon toxin and a
mutant, which contained both H149A and A168F mutations, in
addition to Y30A-Y196A. The authenticity of the proteins was
verified in two ways. First, the genes encoding the mutant genes
were sequenced to validate the presence of the expected
mutation. Second, the purified proteins were analysed by mass
spectrometry to confirm that the experimentally determined mass
matched the expected molecular mass of the protein. For studies
in mice, rabbits or sheep, the proteins had endotoxin levels below
40 endotoxin units/ml.
Thermostability of proteins
The structural stabilities of the wild-type epsilon toxin, the Y30A-
Y196A variant protein and the six mutants of Y30A-Y196A were
assessed using thermostability assays. This revealed that the
melting temperature (Tm in °C) of the Y30A-Y196A variant was
lower than that of wild-type toxin. However, the introduction of
additional mutations (V72F, F92A, H149A, V166A, A168F) into the
Y30A-Y196A variant protein only resulted in small changes in the
thermostability of the proteins (Table 1), indicating that these
substitutions did not destabilise the tertiary structures of the
protein. The Y30A-Y196A-H149A-A168F had the lowest Tm,
indicating that this was the least stable of the mutants tested
(Table 1).
Toxicity of the variant proteins in cell culture
The trypsin-activated purified epsilon toxin proteins were tested
for toxicity towards MDCK.2 cells and CHO cells expressing human
MAL (hMAL) or sheep MAL (sMAL) (Table 2). The Y30A-Y196A
mutations resulted in over 165-fold reduction in toxicity towards
MDCK cells compared to the wild type. However, this mutant
showed 2.3-fold increased toxicity towards CHO cells expressing
hMAL and an 8.6-fold reduction in toxicity towards CHO cells
expressing sMAL, compared with wild-type toxin. Of the mutants
tested, the additional H149A or A168F mutations introduced into
Y30A-Y196A resulted in the most marked reductions in toxicity
towards CHO cells expressing hMAL or sMAL (Table 2).
Toxicity of the variant proteins in mice
The variant proteins that showed the greatest reduction in toxicity
towards CHO-hMAL cell cultures (Y30A-Y196A-H149A, Y30A-
Y196A-A168F and Y30A-Y196A-H149A-A168F) were next tested
for toxicity in mice (Table 2). When given by the intaperitoneal (i.
p.) route, the MLD dose of trypsin-activated wild-type toxin was
between 20 and 200 ng. Compared to the wild type, the MLD
doses of trypsin-activated Y30A-Y196A or Y30A-Y196A-H149A
were reduced 100–1000-fold. The MLD doses of trypsin-activated
Y30A-Y196A-A168F or Y30A-Y196A-H149A-A168F were above the
Fig. 1 Variant proteins tested in this study. a The location of residues previously mutated (Y30 and Y196; ref. 20) are shown in red and the
location of residues in the β-octyl-glucoside binding cleft (V72, F92, H149, V166, A168; ref. 19) mutated in this study are shown in green.
Purified proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and visualised by Coomassie
staining before b and after c activation with trypsin. Lane 1=molecular weight marker (kDa); 2=wild-type toxin; 3= Y30A-Y196A; 4= Y30A-
Y196A-H149A; 5= Y30A-Y196A-A168F; 6= Y30A-Y196A-F92A; 7= Y30A-Y196A-V166A; 8= Y30A-Y196A-V72F; 9= Y30A-Y196A-H149A-A168F.
Gels shown derive from the same experiment and were processed in parallel
Table 1. Melting temperature (Tm) of wild-type and variant
epsilon toxins
Protein Mean Tm (°C) ± SD
Wild-type epsilon toxin 67.4 ± 1.45
Y30A-Y196A 60.6 ± 0.15
Y30A-Y196-A168F 62.0 ± 0.22
Y30A-Y196A-H149A 60.9 ± 2.28
Y30A-Y196A-V166A 59.9 ± 0.47
Y30A-Y196A-V72F 59.5 ± 0.10
Y30A-Y196A-F92A 58.2 ± 0.09
Y30A-Y196A-H149A-A168F 57.4 ± 0.02
Thermostability of proteins was determined by the Boltzmann method
using the Protein Thermal Shift software (Applied Biosystems). Results
represent the mean and standard deviation (SD) of measurements from
duplicate samples
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highest dose tested (20 µg). Without prior activation with trypsin,
the MLD dose was more than 200 µg per mouse. The Y30A-Y196A-
A168F protein was selected for further testing of toxicity by the
subcutaneous (s.c.) route, either before or after trypsin activation.
Antibody responses to the variant proteins
Groups of three rabbits were immunised with the Y30A-Y196A,
Y30A-Y196A-A168F or Y30A-Y196A-H149A-A168F genetic toxoids
given with Freund’s adjuvants. One week after the fourth
immunising dose, serum was tested using a competition
enzyme-linked immunosorbent assay (ELISA) and using an MDCK
neutralisation assay for antibodies against epsilon toxin. In both
assays, we included World Health Organisation (WHO) Interna-
tional Standard epsilon horse antitoxin serum. All of the rabbits
developed antibodies that reacted with wild-type epsilon toxin
when tested using competition ELISA. The titres were broadly
similar in the sera from individual rabbits in each immunisation
group, and therefore we pooled the sera for subsequent tests
(Fig. 2).
We also tested the sera for ability to neutralise toxicity towards
MDCK cells, using an assay previously shown to correlate with the
mouse neutralisation test.23–27 We used WHO International
Standard epsilon horse antitoxin serum, with a known neutralising
antibody titre, to calibrate our assay. The pooled rabbit sera
contained 21 IU/ml (international units/ml) of neutralising
antibody.
Immunisation of lambs
We selected the Y30A-Y196A-A168F protein for testing in sheep
because it had induced a robust antibody response in rabbits,
showed low toxicity in mice, and had a thermostability profile
most similar to the wild-type protein. We immunised groups of
five or six lambs with two doses of Y30A-Y196A-A168F prototoxin
given with either Montanide ISA 61VG or aluminium hydroxide gel
(alhydrogel) adjuvant (Table 3). One additional group of lambs had
pre-existing antibodies against epsilon toxin at the start of the
study, detected using Western blotting, and these lambs were
immunised with two doses of Y30A-Y196A-A168F protein with
Montanide ISA 61VG adjuvant. The sera from these animals and
control sera from lambs, which had not been immunised, were
tested for the presence of antibody able to neutralise epsilon toxin
using three different assays. In all of these assays, we included
dilutions of standardised sera containing a known concentration
of neutralising antibodies, expressed as IU/ml.
The results obtained using an MDCK.2 assay have previously
been shown to correlate with the mouse neutralisation test.23,24
Using this assay we found that at week 13 post immunisation, the
pooled sera from lambs immunised with toxoid in Montanide ISA
61VG adjuvant contained 73 IU/ml of neutralising antibodies
(Table 3). In lambs that had pre-existing antibody and were
immunised with toxoid in Montanide ISA 61VG, the level of
neutralising antibodies was lower (21 IU/ml). We did not detect
antibody in the sera from control lambs or in sera from lambs
immunised with toxoid in alhydrogel using this assay.
We found a similar pattern of results using the competition
ELISA or using an assay where we measured neutralisation
towards CHO-sMAL cells, although the measured levels of
neutralising antibody were higher using these assays than using
the MDCK.2 cell suspension assay (Table 3). Also, using the
competition ELISA we detected low levels of antibodies in the sera
Table 2. Toxicities of the variant proteins tested in this study
Protein Toxicity towards
MDCK cells
Lethality (activated epsilon
toxin) in mice (i.p.)
Lethality (non-activated
epsilon toxin) in mice (s.c.)
Toxicity towards CHO-
hMAL cells
Toxicity towards
CHO-sMAL cells
Wild-type toxin 9.7 ± 1.2 nM 20a–200 ngb ND 12.7 ± 0.68 nM 1.6 ± 0.5 nM
Y30AY-196A 1.6 ± 0.14 µM 2a–20 µgb ND 5.5 ± 0.43 nM 13.75 ± 0.98 nM
Y30AY-196A-
H149A
>6 µM 2a–20 µgb ND >2.5 µM >2 µM
Y30AY-196A-A168F >6 µM 20a–200 µgb >200 µga >2.5 µM >3 µM
Y30AY-196A-F92A 2.76 ± 0.18 µM ND ND 9.94 ± 1.35 nM 47.6 ± 13 nM
Y30AY-196A-
V166A
>3 µM ND ND 14.3 ± 0.98 nM 76.3 ± 11 nM
Y30AY-196A-V72F <3 µM <2 µgb ND >3 µM ND
Y30AY-196A-
H149A-A168F
>6 µM >20 µga ND >3 µM >3 µM
Toxicities towards MDCK cells, CHO-hMAL cells and CHO-sMAL cells are the means of three replicates with standard error of the mean (SEM) values shown
MDCK Madin–Darby canine kidney, CHO Chinese hamster ovary, hMAL human MAL, sMAL sheep myelin and lymphocyte protein, ND not determined
aAll mice (n= 6) survived at this dose
bAll mice (n= 6) reached a humane end point at this dose
Fig. 2 Ability of World Health Organisation (WHO) standard
antitoxin (5 IU/ml) or rabbit sera raised against genetic toxoids to
displace binding of a neutralising monoclonal antibody in a
competitive enzyme-linked immunosorbent assay (ELISA). The sera
were diluted as indicated in the legend before testing. Bars show the
mean of two assays
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from lambs immunised with toxoid in alhydrogel. We also used
the competition ELISA to measure the relative levels of antibodies
up to 12 months after immunisation. At 52 weeks post
immunisation, we were able to detect high levels of neutralising
antibodies (Table 3).
DISCUSSION
In a previous study, we investigated the vaccine potential of a site-
directed mutant of epsilon toxin with mutations in the putative
receptor-binding domain (domain 1; ref. 20). We showed that a
combination of Y30A and Y196A mutations markedly reduced the
ability of the toxin to bind to and kill MDCK cells. We also showed
that Y30A-Y196A had reduced toxicity in mice, suggesting that
Y30A-Y196A mutant could form the basis of an improved
recombinant vaccine against enterotoxaemia (Table 4). Polyclonal
antibody raised against Y30A-Y196A provided protection against
wild-type toxin in an in vitro neutralisation assay.
However, our previous study used the MDCK cell line to
measure cytotoxicity, and subsequently it has been shown that
CHO cell expressing MAL are also highly sensitive to the toxin.12,13
The possibility that MAL is a receptor for the toxin is supported by
the finding that MAL-knockout mice become resistant to the
effects of epsilon toxin12 and by the finding that the toxin can be
isolated from cells complexed with MAL.13 In this study we report
that the Y30A-Y196A mutant is marginally less toxic than wild-type
toxin towards CHO cells expressing sMAL, but is more toxic to
CHO cells expressing hMAL compared to wild-type epsilon toxin.
This finding suggests that MAL from different species interacts
differently with epsilon toxin. Our findings indicate that CHO cells,
which express MAL from the target species to be immunised,
should be used alongside MDCK cells and mice to assess the
toxicity of variant forms of epsilon toxin. Our findings also suggest
that toxicities of epsilon toxin variants in mice may not fully reflect
their likely toxicities in sheep.
In this study, we introduced additional mutations to reduce the
toxicity of Y30A-Y196A towards CHO cells expressing MAL. We
have introduced these mutants into a region in domain 3 that has
been implicated in sugar binding.19 A number of these mutants
showed reduced toxicity in CHO-MAL cell cultures, and also
towards MDCK cells and in mice. While our data do not confirm
the identity of a second receptor binding site, they do confirm the
role of this region in toxicity. We were able to produce all of these
proteins, and on the basis of thermostability measurement, they
did not show major changes in stability, suggesting that the
conformation of the proteins was broadly similar to that of the
wild-type epsilon toxin.
In this study, we measured neutralising antibody using three
tests that avoid the use of mice. One of these tests, using MDCK
cells, has previously shown to provide an accurate indication of
the neutralising antibody titre when tested in mice, and is
therefore an alternative to the mouse lethality test.23–27 The
competitive ELISA and CHO-sMAL cell culture neutralisation test
also revealed the presence of neutralising antibodies to epsilon
toxin in sheep and rabbit sera. Livestock vaccines containing
aluminium hydroxide or saponin as adjuvants often induce short-
lived antibody responses.28 This necessitates boosting at intervals,
sometimes as short as 4 months apart. Montanide ISA 61VG is a
new ready-to-use mineral oil-based adjuvant for use in livestock,
which offers the potential to induce high-level and long-lasting
responses in animals.28 Our finding that the use of Montanide ISA
61VG adjuvant resulted in the induction of better antibody
responses compared to the use of an alhydrogel adjuvant is
similar to previous finding with a foot and mouth disease
vaccine.28 A previous report has also shown that ISA 61VG is
superior to ISA 201VG (water-in-oil) adjuvant or Montanide Gel 01
(aqueous polymer) adjuvant for the induction of antibody
responses.29 We did not see any evidence of local side effectsT
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after using Montanide ISA 61VG adjuvanted protein in lambs,
although others have reported local reactions using this
adjuvant.29
For licensing of epsilon-toxoid vaccine in Europe, compliance
with the European Pharmacopoeia (Ph. Eur.) monograph 0363 on
Clostridium perfringens vaccines for veterinary use30 would be
required. Based on our experimental data we can assess the
likelihood that our Y30A-Y196A-A168F candidate, adjuvanted with
Montanide ISA 61VG, would meet these requirements. European
Pharmacopoeia monograph 0363 requires that mice dosed s.c.
with 0.5 ml of the vaccine do not show signs of intoxication. We
did not detect any sign of toxicity when 200 µg of Y30A-Y196A-
A168F prototoxin was given s.c. to mice, indicating that our
vaccine would comfortably meet the requirement for residual
toxicity. In our studies, lambs were immunised with 200 µg of
toxoid in a total volume of 3 ml. This volume, which is consistent
with the doses of existing commercial vaccines given to sheep,
would indicate a dose of 33 µg of toxoid in 0.5 ml of vaccine.
European Pharmacopoeia monograph 0363 also requires that
rabbits given two minimum doses of vaccines 21–28 days apart
develop neutralising antibody levels of at least 5 IU/ml. We did not
test Y30A-Y196A-A168F adjuvanted with Montanide ISA 61VG in
rabbits. However, the level of neutralising antibodies we elicited in
sheep immunised with two doses of Y30A-Y196A-A168F proto-
toxin adjuvanted with alhydrogel were low. Previously neutralising
antibody levels in the range 8–26 IU/ml have been reported after
immunisation of rabbits or sheep with two doses of 200 µg of
recombinant epsilon toxin, or recombinant E. coli expressing
epsilon toxin, treated with formaldehyde given with aluminium-
based adjuvants.17,31–33 These titres are broadly similar to the
titres reported in sheep (up to 15 IU/ml; refs 33,34) or in goats
(0.22–1.52 IU/ml; refs 35,36) vaccinated with commercially available
vaccines. The neutralising antibody titres that we have found in
sheep dosed with our toxoid with Montanide ISA 61VG adjuvant
are well in excess of the reported minimum protective titres in
sheep (0.1–0.3 IU/ml; refs 34,35) or in goats (1 IU/ml; refs 35,36) and
were still above this threshold 1 year after immunisation.
Additionally, neutralising antibody levels were in excess of the
protective titres after one dose of our vaccine (i.e. at week 3),
indicating that a single dose vaccine for use in livestock is
achievable using this antigen–adjuvant combination.
Our finding that lambs with pre-existing neutralising antibodies
against epsilon toxin responded less well to vaccination is in line
with studies with other vaccines in other species. It is known that
pre-existing antibodies to the antigen can inhibit responses to
vaccines37–40 and it has previously been reported that lambs that
acquire maternal antibody from ewes respond poorly to epsilon
toxin vaccine.34 These pre-existing antibodies might result in
clearance of the antigen or the formation of antigen–antibody
complexes limiting B cell activation or by physically masking the
epitope from B cells.40
The vaccine we have devised here would be used in livestock
susceptible to enterotoxaemia caused by C. perfringens epsilon
toxin. It would have a number of advantages over existing
vaccines because it does not require detoxification before use. The
purity of the antigen and use of an adjuvant such as Montanide
ISA 61VG should promote long-term immunity, reducing or
eliminating the need for booster immunisations. Alternatively, it
may also be possible to use bacteria expressing the toxoid as a
bacterin vaccine. The toxoid could also serve as a protein carrier
for polysaccharides, which induce protective antibodies against
other diseases of livestock.41–46 A glycoconjugate would promote
T cell responses to the polysaccharide moiety47 with increases in
the magnitude of the antibody response and the induction of
memory responses to the polysaccharide.48,49 In addition, the
linking of the polysaccharide to the epsilon toxin carrier would
allow the vaccine to be used in young animals.49 The Y30A-Y196A-
A168F protein could be chemically coupled to polysaccharides or
it could be further modified to serve as an acceptor for
recombinant glycoconjugates generated by exploiting the natu-
rally occurring glycosylation systems in bacteria.50,51
METHODS
Expression and purification of recombinant epsilon toxin mutants
The etxD gene, encoding epsilon prototoxin D from C. perfringens type D
strain NCTC 8346, was cloned into the expression vector pET-26b(+)
(Merck, Darmstadt, Germany) with a N-terminal PelB leader peptide in
place of the 13-amino-acid N-terminal peptide sequence (residues
KEISNTVSNEMSK) and with a C-terminal polyhistidine (6× His) tag to aid
affinity purification of recombinant prototoxin.19 Amino acid numbering
corresponds to prototoxin without the 13-amino-acid N-terminal peptide
sequence. Wild-type recombinant epsilon prototoxin was produced and
purified under ACDP/ACGM containment level 3 conditions.
Mutations H149A, A168F, F92A, V166A, and V72F (residues flanking the
β-octyl-glucoside binding site19) were introduced into the Y30A-Y196A
mutant20 using the QuickChange Lightning Site-Directed Mutagenesis Kit
(Agilent Technologies Inc., Santa Clara, USA) according to the manufac-
turer’s instructions. The presence of the intended mutations was verified
by DNA-sequencing (Eurofins Genomics, Germany). The proteins were
expressed in E. coli Rosetta 2 (DE3) cells (Merck, Darmstadt, Germany) and
grown in ZYM-5052 auto-induction medium52 supplemented with 50 μg/ml
Table 4. Primers used for site-directed mutagenesis
Change Primer sequencea
Y30A Primer ‘Y43A_Forward’: GAAAGGAAGATATAATACAAAATATAATTACTTAAAGAGAATGGAAAAATATGCGCCTAATGCTATGGCATATTTTGATAAGG
Primer ‘Y43A_Reverse’: CCTTATCAAAATATGCCATAGCATTAGGCGCATATTTTTCCATTCTCTTTAAGTAATTATATTTTGTATTATATCTTCCTTTC
Y196A Primer ‘Y209A_Forward’: GTGAATGGGGAGAGATACCTAGTGCGTTAGCTTTTCCTAGGGATGGTTA
Primer ‘Y209A_Reverse’: TAACCATCCCTAGGAAAAGCTAACGCACTAGGTATCTCTCCCCATTCAC
H149A Primer ‘H149A_Forward’: CAAATACAAATACAAATACTAATTCAAAAGAAATTACTGCTAATGTCCCTTCACAAGATATACTA
Primer ‘H149A_Reverse’: TAGTATATCTTGTGAAGGGACATTAGCAGTAATTTCTTTTGAATTAGTATTTGTATTTGTATTTG
V72F Primer ‘V72F_Forward’: AGAACCATCAATGAATTATCTTGAAGATGTTTATTTTGGAAAAGCTCTCTTAAC
Primer ‘V72F_Reverse’: GTTAAGAGAGCTTTTCCAAAATAAACATCTTCAAGATAATTCATTGATGGTTCT
F92A Primer ‘F92A_forward’: TCTTAACTAATGATACTCAACAAGAACAAAAATTAAAATCACAATCAGCGACTTGTAAAAATACTGATACAGTAAC
Primer ‘F92A_reverse’: GTTACTGTATCAGTATTTTTACAAGTCGCTGATTGTGATTTTAATTTTTGTTCTTGTTGAGTATCATTAGTTAAGA
V166A Primer ‘V166A_forward’: ATACTAGTACCAGCTAATACTACTGTAGAAGCGATAGCATATTTAAAAAAAGTTAATGTTAAAG
Primer ‘V166A_Reverse’: CTTTAACATTAACTTTTTTTAAATATGCTATCGCTTCTACAGTAGTATTAGCTGGTACTAGTAT
A168F Primer ‘A168F_Forward’: GATATACTAGTACCAGCTAATACTACTGTAGAAGTAATATTTTATTTAAAAAAAGTTAATGTTAAAGGAAATGTAAAGTTAG
Primer ‘A168F_reverse’: CTAACTTTACATTTCCTTTAACATTAACTTTTTTTAAATAAAATATTACTTCTACAGTAGTATTAGCTGGTACTAGTATATC
aBold bases indicate the codons used for substitution. All primer sequences are shown in 5′ to 3′ orientation
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kanamycin and 34 μg/ml chloramphenicol. Cells (100ml) were grown at
37 °C for 3 h and cultured for a further 24 h at 20 °C, 300 rpm.
For protein purification, cells were harvested by centrifugation, lysed
enzymatically using BugBuster™ Protein Extraction Reagent (Merck,
Darmstadt, Germany), and Y30A-Y196A and its derivatives were purified
by Ni-NTA chromatography columns (GE Healthcare Life Sciences, Little
Chalfont, UK) according to the manufacturer’s instructions. For buffer
exchange and further sample clean up, prototoxin containing eluate was
applied to a PD-10 Desalting Column (GE Healthcare Life Sciences, Little
Chalfont, UK) and eluted in 10mM phosphate buffer, 2.7 mM potassium
chloride, 137mM NaCl, pH 7.4. Protein concentrations were determined
using a BCA assay (Fisher Scientific UK Ltd, Loughborough, UK).
For studies in mice, rabbits or sheep, the proteins were treated to
remove endotoxin using a commercially available kit containing a high
capacity endotoxin removal resin (Pierce™ High Capacity Endotoxin
Removal Spin Columns, Thermo Scientific) according to the manufacturer’s
instructions. Residual levels of endotoxin were measured using a
quantitative chromogenic assay (Pierce LAL Chromogenic Endotoxin
Quantitation Kit, Thermo Scientific).
Trypsin activation
Purified recombinant epsilon prototoxin and its derivatives were activated
with trypsin, TPCK (L-1-tosylamide-2-phenylethyl chloromethyl ketone)
treated, from bovine pancreas (Sigma-Aldrich Company Ltd, Gillingham,
UK), which removes the C-terminal peptide sequence. Trypsin was
prepared in phosphate-buffered saline (PBS) and added to recombinant
prototoxin at 1:100 (w/w) ratio and incubated at room temperature for 1 h.
Protease Inhibitor Cocktail, EDTA free (Fisher Scientific UK Ltd, Loughbor-
ough, UK), was added to the digest to inhibit trypsin in the samples.
Removal of the C-terminal peptide sequence was assessed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
SDS-PAGE analyses
Protein purity was analysed by SDS-PAGE on 4–12% Bis-Tris NuPAGE gels
(Invitrogen Ltd, Paisley, UK) using XCell SureLock™ Mini-Cell Electrophor-
esis System (Invitrogen Ltd, Paisley, UK) and NuPAGE MES SDS running
buffer (Invitrogen Ltd, Paisley, UK). All samples were heated prior to
loading at 70 °C for 10min in NuPAGE LDS sample buffer (Invitrogen Ltd,
Paisley, UK). Gels were typically run at 200 V for 45min. After
electrophoretic separation, proteins were visualised by SimplyBlue staining
(Invitrogen Ltd, Paisley, UK). The Perfect Protein molecular weight standard
(Merck, Darmstadt, Germany) was used as marker.
Thermostability assay
Thermostability was assessed by mixing purified protein (0.25 mg/ml) with
240× SYPRO Orange protein gel stain (Sigma-Aldrich Company Ltd, UK).
Fluorescence was monitored using a StepOnePlus quantitative PCR
machine (Applied Biosystems, USA) with a 1% thermal gradient from 25
to 99 °C. The fluorescence data obtained was analysed using the Protein
Thermal Shift Software (Applied Biosystems, USA) to calculate the Tm using
the Boltzmann method. All measurements were performed in duplicate.
Construction of CHO stable cell line expressing human or sheep
MAL
The hMAL gene (NCBI reference NP_002362.1) or the sMAL gene (NCBI
reference XP_004006224.1) were synthesised (GeneArt, Thermo Fisher
Scientific) with the addition of a 5′ HindIII site and a 3′ BamHI site and each
cloned into pEF1αAcGFP-N1 expression vector (Clontech). After verification
by sequencing, the plasmids were transfected into CHO cells using
Turbofect transfection reagent (Thermo Fisher Scientific) according to the
manufacturer’s instructions. Transfected cells were selected in media
containing 400 μg/ml G418 for 3 weeks to create a clonal pool and clonal
populations expressing hMAL or sMAL were selected and expanded.
Clones were then analysed under a fluorescence microscope (Olympus
X81) to confirm membrane-associated MAL-GFP expression.
Cell culture
MDCK.2 cells (ATCC-LGC Standards, Teddington, UK) were routinely
cultured in Dulbecco’s modified Eagle’s medium/Ham’s F12 (DMEM/F12)
medium (Life Technologies) supplemented with 10% foetal bovine serum
(PAA, Pasching, Austria) at 37 °C in a humidified atmosphere of 95% air/5%
CO2. The culture medium was replaced every 2–3 days. Cells were routinely
detached by incubation in trypsin/EDTA and split as appropriate (typically
1:6 dilutions).
Chinese hamster ovary (CHO) cells or CHO cells expressing green
fluorescent protein (GFP)-tagged hMAL or sMAL were routinely cultured in
Dulbecco’s modified Eagle’s medium/Ham’s F12 (DMEM/F12) medium (Life
Technologies) supplemented with 10% (v/v) foetal bovine serum at 37 °C
in a humidified atmosphere of 95% air/5% CO2. The culture medium was
replaced every 2–3 days. Cells were routinely detached by incubation in
trypsin/EDTA and split as appropriate (typically 1:6 dilutions).
Cytotoxicity assay
The cytotoxic activity of trypsin-activated toxins toward MDCK.2 or CHO
cells expressing MAL was determined by measuring the amount of lactate
dehydrogenase released from the cytosol of lysed cells into the cell culture
medium using the CytoTox 96 Non-radioactive Cytotoxicity Assay Kit
(Promega UK, Southampton, UK) according to the manufacturer’s protocol.
In brief, a two-fold dilution series of each activated toxin (ranging from
10 μM to 0.15 nM) was prepared in PBS and added to cells seeded into 96-
well plate (3 × 104 cells/well). Following incubation at 37 °C for 3 h, the cell
culture medium (50 μl) was harvested from cell monolayers, transferred to
a fresh 96-well enzymatic assay plate and 50 μl of reconstituted substrate
mix was added to each well. The plate was incubated for 30min at room
temperature, protected from light. Absorbance was read at 490 nm using a
Model 680 Microplate Reader (Bio-Rad). The absorbance values for each
sample were normalised by subtracting the absorbance value obtained for
the culture medium from untreated cells. The toxin dose required to kill
50% of the cell monolayer (CT50) was determined by nonlinear regression
analysis (GraphPad). All experiments were performed in triplicate with
three technical replicates each.
Immunisation of rabbits
Groups of three New Zealand White rabbits were each immunised
subcutaneously with 100 µg of Y30A-Y196A, Y30A-Y196A-A168F or Y30A-
Y196A-H149A-A168F by Cambridge Research Biochemicals. Cambridge
Research Biochemicals complies with the Animals (Scientific Procedures)
Act 1986 (ASPA) and all project licences are routinely reviewed by the
Animal Welfare and Ethics Review Board (AWERB) and the Home Office.
Freund’s Complete Adjuvant was used for the initial immunisation and
Freund’s Incomplete Adjuvant was used for four subsequent immunisa-
tions given at 14-day intervals. Blood was collected 7 days after booster
dose 3 (day 49) and 7 days after booster dose 4 (day 63).
Immunisation of sheep with Y30A-Y196A-A168F toxoid
Immunisations were carried out by Orygen Antibodies Ltd (Penicuik,
Scotland). Orygen Antibodies Ltd complies with the Animals (Scientific
Procedures) Act 1986 (ASPA) and all project licences are routinely reviewed
by the Animal Welfare and Ethics Review Board (AWERB) and the Home
Office. Blackface lambs were reared without vaccination against C.
perfringens epsilon toxin and tested at intervals for the presence of
antibody against epsilon toxin using Western blotting.9 Western blots to
compare antibody levels in lambs were processed in parallel. When the
lambs had been weaned and were 12 months old, one group of five lambs
received nothing, one group of six lambs received 200 µg of Y30A-Y196A-
A168F toxoid adjuvanted (1:1) with Montanide ISA 61VG (Seppic, Paris,
France), and a group of five lambs received 200 µg of the Y30A-Y196A-
A168F toxoid adjuvanted with alhydrogel (Sigma-Aldrich, Poole UK; 0.25%
w/v final concentration) adjuvant. We also immunised a group of four
lambs, which had the highest levels of pre-existing reactivity with epsilon
toxin by Western blotting, with 200 µg of the Y30A-Y196A-A168F toxoid
mixed with Montanide ISA 61VG adjuvant (1:1). All of the adjuvanted
mixtures were given s.c. as 6 × 0.5 ml doses. Three weeks later, the lambs
were given a second dose of the adjuvanted protein. Blood samples were
taken at the start of the study and at 3, 7, 13, 16, 25, 38 and 52 weeks post
immunisation.
To measure the level of neutralising antibodies in sera, we also included
dilutions of WHO International Standard C. perfringens epsilon horse
antitoxin serum (National Institute for Biological Standards and Control,
South Mimms, UK), which had known levels of neutralising antibody,
expressed as IU/ml. A dilution series of these sera provided a standard
curve for the calibration of our assays.
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Competition ELISA assay for measuring neutralising antibodies
A competitive ELISA to measure neutralising antibodies was carried out
using a Monoscreen ELISA Kit (BioX Diagnostics, BIO K 222/2) according to
the manufacturer’s instructions. Absorbance was read at 450 nm and
inhibition was calculated using the following formula:
% Inhibition sample= [(OD450 nm negative sera−OD sample)/OD450 nm
negative sera] × 100,
% Inhibition positive= [(OD450 nm negative sera−OD positive sera)/
OO450 nm negative sera] × 100.
The test was validated only if the OD negative−OD positive was >0.7
and inhibition of the positive control was >30%. A dilution series of
International Standard C. perfringens epsilon horse antitoxin serum
provided a standard curve for the calibration of our assays, as
described above.
Neutralisation of toxicity towards cell cultures
We used two different assays to measure neutralisation of toxicity by
antisera. First, we used an assay, using MDCK cells, that has been shown to
correlate with neutralisation in mice.23–27 Briefly, two-fold dilutions of test
sera or standard antitoxin (National Institute of Biological Standards and
Control, 40 IU/ml) were made in Eagle’s minimum essential medium
supplemented with 5% (v/v) foetal bovine serum, non-essential amino
acids, 2 mM L-glutamine and 50 μg/ml gentamicin across a 96-well plate.
Trypsin-activated toxin was diluted in the same media to a final
concentration of 3.15 µg/ml and an equal volume was added to the wells,
followed by incubation at room temperature for 1 h. We added 5 × 103
MDCK.2 cells to each well and the plates were incubated at 37 °C in 95%
air/5% CO2 for 72 h. Cell viability was assessed using the CellTiter 96 Non-
radioactive Cell proliferation assay or MTT assay (Promega).
We also tested the ability of the sera to neutralise toxicity towards CHO
cells expressing sheep MAL. These cells were seeded at 3 × 104 cells per
well of a 96-well plate and left to adhere overnight. Sheep sera from neat
and a standard epsilon antitoxin from 40 IU/ml were diluted in a series of
doubling dilutions in Dulbecco’s phosphate-buffered saline (DPBS) and
incubated with an equal volume of trypsin-activated wild-type epsilon
toxin (5 × CT50) for an hour at room temperature. The CHO-sMAL cells were
washed twice with serum-free DMEM/F12 and the toxin:antibody/standard
antitoxin mix was then added, along with DPBS-only and toxin-only
controls (final concentration 5 × CT50), to the cells. Following incubation for
3 h at 37 °C in a humidified atmosphere, the media were replaced with
100 μl of fresh serum-free DMEM/F12 and 10 μl of WST-1 cell proliferation
reagent (Abcam). The formazan dye produced by viable cells was
quantified by measuring the absorbance at 420 nm after incubation for
1 h at 37 °C in a humidified atmosphere.
Toxicity in mice
Groups of six female 8-week-old BALB/c mice (17–22 g) were challenged
by the i.p. or s.c. route with either non-activated or trypsin-activated
protein in 100 μl volumes. The experiments were terminated at 24 h post i.
p. challenge or 7 days post s.c. challenge. The studies were performed with
the approval of the University of Exeter ethics committee. At appropriate
intervals, the animals were assessed for neurological symptoms, changes in
appearance or changes in behaviour according to a pre-determined
scoring matrix. Animals with a combined score of 5 or more were culled.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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